Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy.

× No keyword cloud information.

6 in total

1. Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis.

Authors: D Cunningham; A Turner; J Hawthorn; R D Rosin
Journal: Lancet Date: 1989-06-10 Impact factor: 79.321

2. Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.

Authors: M G Kris; R J Gralla; R A Clark; L B Tyson
Journal: J Clin Oncol Date: 1988-04 Impact factor: 44.544

3. 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis.

Authors: B Costall; A M Domeney; R J Naylor; F D Tattersall
Journal: Neuropharmacology Date: 1986-08 Impact factor: 5.250

4. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism.

Authors: W D Miner; G J Sanger
Journal: Br J Pharmacol Date: 1986-07 Impact factor: 8.739

5. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.

Authors: D Cunningham; J Hawthorn; A Pople; J C Gazet; H T Ford; T Challoner; R C Coombes
Journal: Lancet Date: 1987-06-27 Impact factor: 79.321

6. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients.

Authors: M G Kris; R J Gralla; L B Tyson; R A Clark; D P Kelsen; L K Reilly; S Groshen; G J Bosl; L A Kalman
Journal: Cancer Date: 1985-02-01 Impact factor: 6.860

6 in total

14 in total

Review 1. Neuropharmacology of emesis in relation to clinical response.

Authors: B Costall; R J Naylor
Journal: Br J Cancer Suppl Date: 1992-12

Review 2. Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy.

Authors: G L Plosker; R J Milne
Journal: Pharmacoeconomics Date: 1992-10 Impact factor: 4.981

Review 3. Ondansetron. Therapeutic use as an antiemetic.

Authors: R J Milne; R C Heel
Journal: Drugs Date: 1991-04 Impact factor: 9.546

Review 4. Antiemetics in cancer chemotherapy: historical perspective and current state of the art.

Authors: M Tonato; F Roila; A Del Favero; E Ballatori
Journal: Support Care Cancer Date: 1994-05 Impact factor: 3.603

Review 5. [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].

Authors: A Du Bois
Journal: Med Klin (Munich) Date: 1998-01

Review 6. Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities.

Authors: A Del Favero; F Roila; M Tonato
Journal: Drug Saf Date: 1993-12 Impact factor: 5.606

Review 7. 5-Hydroxytryptamine (serotonin) subtype 3 antagonists, a major step in prophylaxis and control of cytostatic and radiation-induced emesis.

Authors: K Bremer
Journal: J Cancer Res Clin Oncol Date: 1991 Impact factor: 4.553

Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy.